

416 Rec'd PCT/PTO 11 FEB 2000

Page 1 of 1 FORM PTO 1449 (modified)				ATTY DOCKET NO.: 2477US0P	SERIAL NO. 09 / 485640		
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO:				APPLICANT: H. ODAKA et al.			
				FILING DATE:	GROUP:		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>Saq</i>	A1	WO 97/45141	Dec. 4, 1997	WIPO			English Abstract
	A2	WO 96/34943	Nov. 7, 1996	WIPO			
	A3	WO 95/35108	Dec. 28, 1995	WIPO			
	A4	WO 97/37688	Oct. 16, 1997	WIPO			
	A5	WO 96/24350	Aug. 15, 1996	WIPO			
	A6	JP 7-285864	Oct. 31, 1995	Japan			English Abstract
<i>Saq</i>	A7	DE 19540475 A1	Apr. 24, 1997	Germany			English Abstract
OTHER DOCUMENT(S)							
*EXAMINER INITIAL	REF No.	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.					
<i>Saq</i>	A8	A. Okuno et al. "Thiazolidine Derivatives and Insulin Resistance Amelioration" The Saishin-Igaku , Vol. 52(6) (1997), pp.1153-1160 (with English translation)					
<i>Saq</i>	A9	C. Hofmann et al. "Altered Gene Expression for Tumor Necrosis Factor- α and Its Receptors during Drug and Dietary Modulation of Insulin Resistance" Endocrinology, Vol. 134, No. 1 (January 1994), pp.264-270					
<i>Saq</i>	A10	D. Szalkowski et al. "Antidiabetic Thiazolidinediones Block the Inhibitory Effect of Tumor Necrosis Factor- α on Differentiation, Insulin-Stimulated Glucose Uptake, and Gene Expression in 3T3-L1 Cells" Endocrinology, Vol. 136, No. 4 (April 1995), pp.1474-1481					
	A11	M. Missbach et al. "Thiazolidine Diones, Specific Ligands of the Nuclear Receptor Retinoid Z Receptor/Retinoid Acid Receptor-related Orphan Receptor α with Potent Antiarthritic Activity" The Journal of Biological Chemistry Vol. 271, No. 23, Issue of June 7(1996), pp. 13515-13522					
<i>Saq</i>	A12	R.W. Stevenson et al. "The thiazolidinedione drug series" The Diabetes Annual Vol. 9 (1995) , pp.175-191					
<i>Saq</i>	A13	T. Yoshimoto et al. "Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats" The American Physiological Society , Vol. 272, No. 6 Part 1(June 1997), pp.E989-E996					
<i>Saq</i>	A14	S.S.Solomon et al. "Pioglitazone and Metformin Reverse Insulin Resistance Induced by Tumor Necrosis Factor-Alpha in Liver Cells" Horm. Metab. Res. Vol. 29, No. 8 (August 1997), pp.379-382					
<i>Saq</i>	A15	H. Odaka et al. "Effect of Pioglitazone on Sucrose-Deteriorated Diabetic States in Spontaneously Diabetic GK Rats" J. Jpn. Diabetes Soc. 34(6), 1991, pp. 523-530 (only English Abstract)					
	A16	H. Suzuki et al. "Nephropathy in genetically obese-diabetic Wistar fatty rats-Characterization and prevention" Japanese Pharmacology and Therapeutics Vol. 25, No. 2, 1997, pp.43-51 (only English Abstract)					
	A17	P. Peraldi et al "Thiazolidinediones Bloc Tumor Necrosis Factor- α -induced Inhibition of Insulin Signaling" J. Clin. Invest., Vol. 100, No. 7 (October 1997), pp.1863-1869					
<i>Saq</i>	A18	S.L.Grossman et al. "Mechanisms and clinical effects of thiazolidinediones" Exp. Opin. Invest. Drugs Vol. 6, No. 8 (August 1997), pp.1025-1040					
EXAMINER:	<i>Saq</i>			DATE CONSIDERED: 6/5/01			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609/ Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.